Brolucizumab: is extended VEGF suppression on the horizon?
- 16 September 2019
- journal article
- editorial
- Published by Springer Nature in Eye
- Vol. 34 (3) , 424-426
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular DegenerationOphthalmology, 2019
- Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular DegenerationJournal of Ocular Pharmacology and Therapeutics, 2018
- Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized TrialOphthalmology, 2017
- Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degenerationPsychology, Health & Medicine, 2017
- Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular DegenerationOphthalmology, 2016
- Ranibizumab for the treatment of wet AMD: a summary of real-world studiesEye, 2015
- A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degenerationBritish Journal of Ophthalmology, 2015
- Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab TreatmentPLOS ONE, 2014
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1American Journal of Ophthalmology, 2008